LM
Therapeutic Areas
Aligos Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Pevifoscorvir sodium (ALG-000184) | Chronic Hepatitis B (CHB) | Phase 2 |
| ALG-055009 | Metabolic dysfunction-associated steatohepatitis (MASH) | Phase 2 |
| ALG-125755 | Chronic Hepatitis B (CHB) | Phase 1 |
| ALG-097558 | COVID-19 | Preclinical |